New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: A comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3730-3737

  Krudsood, S ^a   Looareesuwan, S ^a   Tangpukdee, N ^a   Wilairatana, P ^a   Phumratanaprapin, W ^a   Leowattana, W ^a   Chalermrut, K ^a   Ramanathan, S ^b   Navaratnam, V ^b   Olliaro, P ^c   Vaillant, M ^d   Kiechel, J R ^e   Taylor, W R J ^c,f  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SCHOOL OF PHYSICS   (Malaysia)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^e Drugs for Neglected Diseases Initiative   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BILIRUBIN; CREATININE; DIHYDROARTEMISININ; DOPAMINE; HEMOGLOBIN; INFUSION FLUID; MEFLOQUINE;

ABDOMINAL PAIN; ABSCESS; ADOLESCENT; ADULT; ANEMIA; ANOREXIA; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EOSINOPHILIA; EPISTAXIS; FEMALE; FLATULENCE; HEADACHE; HEART PALPITATION; HEART RATE; HELMINTH; HEMATOLOGY; HEMATURIA; HORDEOLUM; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; LEUKOCYTE; LEUKOCYTE COUNT; MALARIA; MALE; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NECK PAIN; NOSE CONGESTION; PLASMODIUM FALCIPARUM; PR INTERVAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEAKNESS;

EID: 77956127869     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01187-09     Document Type: Article

References (35)

1. Adjuik, M., P. Agnamey, A. Babiker, S. Borrmann, P. Brasseur, M. Cisse, F. Cobelens, S. Diallo, J. F. Faucher, P. Garner, S. Gikunda, P. G. Kremsner, S. Krishna, B. Lell, M. Loolpapit, P. B. Matsiegui, M. A. Missinou, J. Mwanza, F. Ntoumi, P. Olliaro, P. Osimbo, P. Rezbach, E. Some, and W. R. Taylor. 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359:1365-1372.
2. Adjuik, M., A. Babiker, P. Garner, P. Olliaro, W. Taylor, and N. White. 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363:9-17.
3. Angus, B. J., I. Thaiaporn, K. Chanthapadith, Y. Suputtamongkol, and N. J. White. 2002. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob. Agents Chemother. 46:778-782.
4. Anonymous. 2000. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):S1-S90.
5. Ashley, E. A., K. M. Lwin, R. McGready, W. H. Simon, L. Phaiphun, S. Proux, N. Wangseang, W. Taylor, K. Stepniewska, W. Nawamaneerat, K. L. Thwai, M. Barends, W. Leowattana, P. Olliaro, P. Singhasivanon, N. J. White, and F. Nosten. 2006. An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop. Med. Int. Health 11:1653-1660.
6. Ashley, E. A., K. Stepniewska, N. Lindegardh, R. McGready, R. Hutagalung, R. Hae, P. Singhasivanon, N. J. White, and F. Nosten. 2006. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 50:2281-2285.
7. Bethell, D. B., P. Teja-Isavadharm, X. T. Cao, T. T. Pham, T. T. Ta, T. N. Tran, T. T. Nguyen, T. P. Pham, D. Kyle, N. P. Day, and N. J. White. 1997. Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 91:195-198.
8. Carrara, V. I., J. Zwang, E. A. Ashley, R. N. Price, K. Stepniewska, M. Barends, A. Brockman, T. Anderson, R. McGready, L. Phaiphun, S. Proux, M. van Vugt, R. Hutagalung, K. M. Lwin, A. P. Phyo, P. Preechapornkul, M. Imwong, S. Pukrittayakamee, P. Singhasivanon, N. J. White, and F. Nosten. 2009. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4551.
9. Chongsuphajaisiddhi, T., A. Sabchareon, P. Chantavanich, V. Singhasivanon, P. Attanath, W. H. Wernsdorfer, and U. K. Sheth. 1987. A phase-III clinical trial of mefloquine in children with chloroquine-resistant falciparum malaria in Thailand. Bull. World Health Organ. 65:223-226.
10. Davis, T. M., M. Ho, W. Supanaranond, S. Looareesuwan, S. Pukrittayakamee, and N. J. White. 1991. Changes in the peripheral blood eosinophil count in falciparum malaria. Acta Trop. 48:243-246.
11. Edwards, I. R., and J. K. Aronson. 2000. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255-1259.
12. Gutman, J., M. Green, S. Durand, O. V. Rojas, B. Ganguly, W. M. Quezada, G. C. Utz, L. Slutsker, T. K. Ruebush II, and D. J. Bacon. 2009. Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. Malar. J. 8:58.
13. Lai, C. S., N. K. Nair, S. M. Mansor, P. L. Olliaro, and V. Navaratnam. 2007. An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 857:308-314.
14. Laothavorn, P., J. Karbwang, K. Na Bangchang, D. Bunnag, and T. Harinasuta. 1992. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. Southeast Asian J. Trop. Med. Public Health 23:51-54.
15. Leonardi, E., G. Gilvary, N. J. White, and F. Nosten. 2001. Severe allergic reactions to oral artesunate: a report of two cases. Trans. R. Soc. Trop. Med. Hyg. 95:182-183.
16. Lightbown, I. D., J. P. Lambert, G. Edwards, and S. J. Coker. 2001. Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. Br. J. Pharmacol. 132:197-204.
17. Looareesuwan, S., T. Harinasuta, and T. Chongsuphajaisiddhi. 1992. Drug resistant malaria, with special reference to Thailand. Southeast Asian J. Trop. Med. Public Health 23:621-634.
18. Luxemburger, C., F. Nosten, F. ter Kuiile, L. Frejacques, T. Chongsuphajaisiddhi, and N. J. White. 1991. Mefloquine for multidrug-resistant malaria. Lancet 338:1268.
19. Luxemburger, C., R. N. Price, F. Nosten, F. O. Ter Kuile, T. Chongsuphajaisiddhi, and N. J. White. 1996. Mefloquine in infants and young children. Ann. Trop. Paediatr. 16:281-286.
20. Newton, P., Y. Suputtamongkol, P. Teja-Isavadharm, S. Pukrittayakamee, V. Navaratnam, I. Bates, and N. White. 2000. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob. Agents Chemother. 44:972-977.
21. Nosten, F., C. Luxemburger, F. O. ter Kuile, C. Woodrow, J. P. Eh, T. Chongsuphajaisiddhi, and N. J. White. 1994. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J. Infect. Dis. 170:971-977.
22. Nosten, F., F. O. ter Kuile, C. Luxemburger, C. Woodrow, D. E. Kyle, T. Chongsuphajaisiddhi, and N. J. White. 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341:1054-1056.
23. Nosten, F., M. van Vugt, R. Price, C. Luxemburger, K. L. Thway, A. Brockman, R. McGready, F. ter Kuile, S. Looareesuwan, and N. J. White. 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356:297-302.
24. Price, R., J. A. Simpson, P. Teja-Isavatharm, M. M. Than, C. Luxemburger, D. G. Heppner, T. Chongsuphajaisiddhi, F. Nosten, and N. J. White. 1999. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob. Agents Chemother. 43:341-346.
25. Price, R., M. van Vugt, L. Phaipun, C. Luxemburger, J. Simpson, R. McGready, F. ter Kuile, A. Kham, T. Chongsuphajaisiddhi, N. J. White, and F. Nosten. 1999. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60:547-555.
26. Rowland, M., and T. Tozer. 1989. Clinical pharmacokinetics: concepts and applications. Lea and Feiber, Philadelphia, PA.
27. Simpson, J. A., R. Price, F. ter Kuile, P. Teja-Isavatharm, F. Nosten, T. Chongsuphajaisiddhi, S. Looareesuwan, L. Aarons, and N. J. White. 1999. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 66:472-484.
28. Simpson, J. A., E. R. Watkins, R. N. Price, L. Aarons, D. E. Kyle, and N. J. White. 2000. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44:3414-3424.
29. Slutsker, L. M., C. O. Khoromana, D. Payne, C. R. Allen, J. J. Wirima, D. L. Heymann, L. Patchen, and R. W. Steketee. 1990. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull. World Health Organ. 68:53-59.
30. Snounou, G., and H. P. Beck. 1998. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol. Today 14:462-467.
31. Taylor, W. R., and N. J. White. 2004. Antimalarial drug toxicity: a review. Drug Saf. 27:25-61.
32. Taylor, W. R., H. Widjaja, H. Basri, C. Ohrt, T. Taufik, E. Tjitra, S. Baso, D. Fryauff, S. L. Hoffman, and T. L. Richie. 2008. Changes in the total leukocyte and platelet counts in Papuan and non-Papuan adults from north-east Papua infected with acute Plasmodium vivax or uncomplicated Plasmodium falciparum malaria. Malar. J. 7:259.
33. Teja-Isavadharm, P., G. Watt, C. Eamsila, K. Jongsakul, Q. Li, G. Keeratithakul, N. Sirisopana, L. Luesutthiviboon, T. G. Brewer, and D. E. Kyle. 2001. Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 65:717-721.
34. ter Kuile, F. O., F. Nosten, C. Luxemburger, D. Kyle, P. Teja-Isavatharm, L. Phaipun, R. Price, T. Chongsuphajaisiddhi, and N. J. White. 1995. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull. World Health Organ. 73:631-642.
35. Touze, J. E., P. Heno, L. Fourcade, J. C. Deharo, G. Thomas, S. Bohan, P. Paule, P. Riviere, E. Kouassi, and A. Buguet. 2002. The effects of antimalarial drugs on ventricular repolarization. Am. J. Trop. Med. Hyg. 67:54-60.